GENE ONLINE|News &
Opinion
Blog

2022-09-16| COVID-19Special

The COVID-19 Pandemic: Is Omicron the Last Variant?

by Max Heirich
Share To
The COVID-19 pandemic saw the rise of multiple strains that put the companies manufacturing vaccines through their paces to keep up. With the FDA approving new vaccines for the latest substrains of the Omicron Variant, it seems that COVID-19 Cases are finally slowing down. These Emergency Use Authorizations were pushed through in a manner of days, marking them as some of the fastest ever in FDA history. However, they were based upon mountains of prior research done on their predecessors for prior strains as well as the heavily mutated Omicron Strains.
How do these vaccines function differently from their prior counterparts? And will these boosters bring about the end of the COVID-19 pandemic after so many strain mutations?

GO Prime with only $1.49 now

LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!